Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — April 2019

Planlagt Fastgjort Låst Flyttet Genmab
1.3k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • E Offline
    E Offline
    E_L
    wrote on sidst redigeret af
    #388

    sounds positive to me they are doing this and indicates they have not yet found major safety issues with IV and found a "safe dose"

    1 Reply Last reply
    0
    • E Offline
      E Offline
      E_L
      wrote on sidst redigeret af
      #389

      i think they did something similar to this, earlier this year with the CD3 GPRC5D trial

      1 Reply Last reply
      0
      • K Offline
        K Offline
        kkjoel
        wrote on sidst redigeret af
        #390

        A very good little piece of news: sc-arms on BCMAxCD3 study - tnx EL 🙂

        1 Reply Last reply
        0
        • K Offline
          K Offline
          kkjoel
          wrote on sidst redigeret af
          #391

          They keep popping up... those small pieces of good news, don't they? Hard to keep pessimisticism!

          1 Reply Last reply
          0
          • J Offline
            J Offline
            JKY_VH
            wrote on sidst redigeret af
            #392

            tak E L

            1 Reply Last reply
            0
            • P Offline
              P Offline
              peter12
              wrote on sidst redigeret af
              #393

              AQR har reduceret til 1,88% dvs 0,11% ?

              1 Reply Last reply
              0
              • P Offline
                P Offline
                peter12
                wrote on sidst redigeret af
                #394

                I går

                1 Reply Last reply
                0
                • D Offline
                  D Offline
                  Doc4
                  wrote on sidst redigeret af
                  #395

                  Her lidt om omkostninger for Dara kombier...RESULTS:
                  The estimated cost per patient for each triplet regimen was $13,890 (DARA/BOR/DEX), $22,231 (IXA/LEN/DEX), $24,322 (ELO/LEN/DEX), $26,410 (DARA/LEN/DEX), and $27,432 (CAR/LEN/DEX). Drug acquisition costs and treatment duration were the largest drivers of cost. https://www.ncbi.nlm.nih.gov/pubmed/30917078

                  1 Reply Last reply
                  0
                  • D Offline
                    D Offline
                    Doc4
                    wrote on sidst redigeret af
                    #396

                    Single-agent daratumumab in very advanced relapsed and refractory multiple myeloma patients: a real-life single-center retros.These real-life results revealed modest efficacy of single-agent daratumumab in advanced patients with RRMM in comparison with data from clinical trials. The overall response rate was 24%, including 5% very good partial response or better. After a median follow-up of 6.5 months, all patients experienced disease relapse. The median progression-free survival was 1.9 mo.

                    1 Reply Last reply
                    0
                    • D Offline
                      D Offline
                      Doc4
                      wrote on sidst redigeret af
                      #397

                      https://www.ncbi.nlm.nih.gov/pubmed/30874850

                      1 Reply Last reply
                      0
                      • P Offline
                        P Offline
                        peter12
                        wrote on sidst redigeret af
                        #398

                        "Most patients presented with high-risk characteristics", så det er vel ikke en normal gruppe ?

                        1 Reply Last reply
                        0
                        • BulderB Offline
                          BulderB Offline
                          Bulder
                          wrote on sidst redigeret af
                          #399

                          Lidt ringere end Sirius. 24% ORR vs 29% og median PFS 1,9 md vs. 3,7 md. Median antal forudgående behandlinger 4 vs 5. Om patienterne iøvrigt er sammenlignelige ved jeg ikke. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)01120-4/fulltext

                          1 Reply Last reply
                          0
                          • B Offline
                            B Offline
                            bibob
                            wrote on sidst redigeret af
                            #400

                            Det er jo ikke kun Genmab. Markedet afventer nogle nøgletal i slut ugen. Faldet har ikke noget med hverken dårlige eller gode nyheder at gøre ift Genmab.

                            1 Reply Last reply
                            0
                            • BulderB Offline
                              BulderB Offline
                              Bulder
                              wrote on sidst redigeret af
                              #401

                              Vi må håbe at Car-t kommer ind her med noget bedre når dara/imid kombierne er udtømte.

                              1 Reply Last reply
                              0
                              • Helge_LarsenPI-redaktørH Offline
                                Helge_LarsenPI-redaktørH Offline
                                Helge_LarsenPI-redaktør
                                wrote on sidst redigeret af
                                #402

                                Enig bibob . Alt ser rød ud her hos mig. 😞

                                1 Reply Last reply
                                0
                                • Helge_LarsenPI-redaktørH Offline
                                  Helge_LarsenPI-redaktørH Offline
                                  Helge_LarsenPI-redaktør
                                  wrote on sidst redigeret af
                                  #403

                                  Ham her er ikke ked af det. https://play.borsen.dk/social/5cac6c6e595ab4f00a3311e8

                                  1 Reply Last reply
                                  0
                                  • D Offline
                                    D Offline
                                    Doc4
                                    wrote on sidst redigeret af
                                    #404

                                    T-cell acute lymphoblastic leukaemia (T-ALL) - “Dar”-ing to target CD38 in T-ALL. T-cell acute lymphoblastic leukemia = T-ALL. ..."This study is compelling because it provides strong evidence that daratumumab should have clinical efficacy in T-ALL"

                                    1 Reply Last reply
                                    0
                                    • D Offline
                                      D Offline
                                      Doc4
                                      wrote on sidst redigeret af
                                      #405

                                      favicon

                                      (www.bloodjournal.org)

                                      1 Reply Last reply
                                      0
                                      • T Offline
                                        T Offline
                                        transalp
                                        wrote on sidst redigeret af
                                        #406

                                        Øhhe det lyder ret positivt 🙂 Doc4, den smule som lægmand forstår.. tak for link..

                                        1 Reply Last reply
                                        0
                                        • J Offline
                                          J Offline
                                          jkj
                                          wrote on sidst redigeret af
                                          #407

                                          Ifølge FDA,s tidsplan for RTOR, så bør godkendelse af Dara til 1 Linje komme i indeværende uge.

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger